Evidence map›Paper›PMID 32289161›Full record

ArticleBlood advances2020

Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

Omar Niss, Adam Lane, Monika R Asnani, Marianne E Yee, Ashok Raj, Susan Creary, Courtney Fitzhugh, Prasad Bodas, Santosh L Saraf, Sharada Sarnaik and 2 more

2 registry-linked trialsOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02239016 completednot on this map

Screening Patients With Sickle Cell Disease for Kidney Damage

TypeobservationalSponsorChildren's Hospital Medical Center, CincinnatiRan2009 to 2020Enrolled320ConditionsSickle Cell Disease
NCT07175051 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin

TypeinterventionalSponsorUniversity of Illinois at ChicagoRan2026 to 2030Enrolled20ConditionsSickle Cell Anemia (HbSS, or HbSβ-thalassemia0), AlbuminuriaArmsEmpagliflozin (oral)
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Management of Kidney Disease with Sickle Cell Disease.Journal of the American Society of Nephrology : JASN · 2025
    Review
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 2 countries.

Omar NissDivision of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Adam LaneDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Monika R AsnaniSickle Cell Unit, Caribbean Institute for Health Research, University of the West Indies, Kingston, Jamaica.
Marianne E YeeAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.
Ashok RajDepartment of Pediatrics, University of Louisville, Louisville, KY.
Susan CrearyCenter for Innovation in Pediatric Practice, Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH.
Courtney FitzhughHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
Prasad BodasAkron Children's Hospital, Akron, OH.
Santosh L SarafDivision of Hematology Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL.
Sharada SarnaikChildren's Hospital of Michigan, Detroit, MI; and.
Prasad DevarajanDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Punam MalikDivision of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Cincinnati Children's Hospital Medical Center · USAkron Children's Hospital · USChildren's Hospital of Michigan · USEmory University · USNational Institutes of Health · USNationwide Children's Hospital · USPediatric Nephrology of Alabama · USUniversity of Illinois Chicago · USUniversity of Louisville · USUniversity of the West Indies · JM

Funding

Cincinnati Center of Excellence in Hemoglobinopathies ResearchU01HL117709 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI MALIK, PUNAM · 2013 to 2017
$8.9M
Proteomics CoreP50DK096418 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 2012 to 2021
$8.4M
Genetics and Genomics of Sickle Cell Nephropathy.K23HL125984 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2015 to 2018
$700k
Ameliorating Sickle Nephropathy and Pulmonary HypertensionR34HL108752 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI MALIK, PUNAM · 2011 to 2013
$602k
Cell-free Hemoglobin in Sickle Cell Acute Kidney InjuryR03HL146788 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2019 to 2020
$160k
NHLBI NIH HHS K23 HL125984NHLBI NIH HHS R03 HL146788NHLBI NIH HHS R34 HL108752NHLBI NIH HHS U01 HL117709NIDDK NIH HHS P50 DK096418
6 · The paper itself

Abstract

Sickle cell nephropathy results in chronic kidney disease (CKD), which is associated with significant morbidity and mortality in sickle cell anemia (SCA). Albuminuria is an early manifestation of sickle nephropathy; however, little is known about progression of albuminuria or its correlation with glomerular filtration rate (GFR) decline or CKD. We studied nephropathy progression in 303 SCA participants in a prospective, multicenter, longitudinal study. We collected steady-state urine and serum samples yearly and assessed albumin/creatinine ratio (ACR), estimated GFR (eGFR), and SCA and nephropathy biomarkers. Participants with albuminuria (ACR ≥30 mg/g) for ≥2 annual measurements were classified as having persistent albuminuria (PA). At baseline (mean age, 21 years; range, 2-64 years), 32% had albuminuria. In longitudinal multivariate analysis, ACR was associated with sex, anemia, older age, and higher bilirubin and kidney injury molecule-1 levels. Albuminuria increased with age by 3.5 mg/g per year (P < .0001). Of 175 participants with ≥3 annual samples, 81% with baseline albuminuria ≥100 mg/g developed PA. Decreased eGFR and adult CKD were associated with PA (P = .002 and P = .02, respectively), but not with baseline albuminuria. Rate of eGFR decline was steeper among adults (but not children) with albuminuria, compared with those without (P = .02). Participants with PA were more likely to have rapid eGFR decline compared with those without (P = .03). In this longitudinal study, albuminuria progressed with age, and adults with albuminuria had worse eGFR decline than those without. Albuminuria ≥100 mg/g predicted PA, which was associated with rapid eGFR decline and CKD development in adults with SCA. This trial was registered at www.clinicaltrials.gov as #NCT02239016.

Indexed as

AlbuminuriaAnemia, Sickle CellAdultAgedGlomerular Filtration RateHumansLongitudinal StudiesProspective StudiesYoung Adult

Identifiers

PMID32289161
PMCPMC7160281
OpenAlexW3015194280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.